WuXi AppTec (603259.SH): The transaction of WuXi ATU business is expected to be completed in the first half of 2025.

WuXi AppTec (603259.SH) announced that its indirect wholly-owned subsidiaries, WuXi ATU (Ireland) Holding Limited, WuXi ATU (Hong Kong) Limited, and Altaris LLC (including its controlled entities, referred to as "Altaris"), signed a Share Purchase Agreement on December 24, 2024 (US time). They will transfer all the equity interests they hold in WuXi Advanced Therapies Inc. (the US operating entity of WuXi ATU business, referred to as "Advanced Therapies") and Oxford Genetics Limited (the UK operating entity of WuXi ATU business, referred to as "Oxford Genetics") to Altaris in exchange for cash. Altaris is a US-based private equity fund specializing in the healthcare industry. The announcement states that the company's management believes that the transaction will ensure uninterrupted services and timely treatment for all customers and patients in urgent need of WuXi ATU cell therapy services. Additionally, the relevant scientists, technical personnel, and other employees of WuXi ATU's US and UK businesses can continue to work towards the mission of "making medicines accessible and diseases curable." This transaction aligns with the company's core values of prioritizing customers and patients first and is not expected to have a significant impact on the company's performance and business operations. The company will continue to adhere to its strategic goals of "following customers" and "following molecules" and will continue to strive for the great vision of "making medicines accessible and diseases curable." Advanced Therapies and Oxford Genetics are the operating entities engaged in high-end therapy CTDMO businesses in the US and UK for the company. In the period from January to November 2024, the combined operating revenue of Advanced Therapies and Oxford Genetics was approximately RMB 980 million (unaudited), accounting for 2.4% of the company's audited operating revenue for the most recent financial year. The completion of this transaction is subject to the terms of the Share Purchase Agreement and is expected to be finalized in the first half of 2025. The company will issue further progress announcements following the completion of the transaction.